Avadel Pharma (AVDL) Tops Q3 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Avadel Pharmaceuticals Reports Third Quarter 2017 Results
November 8, 2017 7:30 AM ESTTotal Revenues for the Third Quarter Were $39.7 Million
Full Year Revenue Guidance of $165-$175 Million Unchanged
Acquired License for Noctiva
DUBLIN, Ireland, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (NASDAQ: AVDL) today announced its financial results for the third quarter ended September 30, 2017.
Highlights Include:
Total revenues for the third quarter 2017 were $39.7 million, compared to $32.1 million in the third quarter... More